Cancellation of state registration. Dalacine C® phosphate

August 30, 2017
Active substances:
Trade names:
ICD-10:
X.J10-J18.J15    Bacterial pneumonia, not elsewhere classified
X.J85-J86.J85    Abscess of the lung and mediastinum
X.J85-J86.J86    Pythothrace
XI.K65-K67.K65.0    Acute peritonitis
XII.L00-L08.L01    Impetigo
XII.L00-L08.L02    Abscess of skin, boil and carbuncle
XII.L00-L08.L03    Phlegmon
XII.L00-L08.L08.0    Pyoderma
XII.L60-L75.L70    Acne
XIII.M86-M90.M86    Osteomyelitis
XIV.N70-N77.N70    Salpingitis and oophoritis
XIV.N70-N77.N72    Inflammatory disease of the cervix
XIV.N70-N77.N71.9    Inflammatory disease of uterus, unspecified
XIV.N70-N77.N73.0    Acute parametritis and pelvic cellulite
XIV.N70-N77.N76    Other inflammatory diseases of the vagina and vulva
XIX.T79.T79.3    Post-traumatic wound infection, not elsewhere classified
XXI.Z20-Z29.Z29.2    Another type of preventive chemotherapy
Dalacine TS phosphate, clindamycin, infectious-inflammatory diseases of severe course, empyema, pneumonia, lung abscess, osteomyelitis, purulent infections of the skin, soft tissue injuries, endometritis, adnexitis, peritonitis, vaginosis

Russian Ministry of Health in accordance with Article 32 of the Federal Law of 12.04.2010 number 61-FZ "On Circulation of Medicines" decided to cancel state registration and exclusion from the state register of medicines for medical use of the drug (registration certificate P N013455 / 01 from 04.12.2008 issued by Pfizer IFG Belgium N. V., Belgium):

Dalacine C® phosphate (trade name of the drug)

Clindamycin (international non-proprietary or grouping or chemical name)

solution for intravenous and intramuscular administration, 150 mg / ml (dosage form, dosage)

Pfizer MFG. Belgium NV, Belgium Rijksweg 12,2870 Puurs, Belgium (name and address of the location of the manufacturer of the medicinal product)

on the basis of filing an application by an authorized legal entity LLC Pfizer for the abolition of state registration of a medicinal product.